Regen BioPharma, Inc.
RGBP
$0.058
-$0.0034-5.54%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.17% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.17% |
| SG&A Expenses | 23.57% | 16.50% | -29.56% | -34.55% | -38.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.15% | 1.85% | -29.12% | -34.79% | -35.37% |
| Operating Income | -0.24% | -3.18% | 39.11% | 46.12% | 47.35% |
| Income Before Tax | -34.44% | -65.50% | -157.28% | -151.48% | -101.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.44% | -65.50% | -157.28% | -151.48% | -101.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.44% | -65.50% | -157.28% | -151.48% | -101.01% |
| EBIT | -0.24% | -3.18% | 39.11% | 46.12% | 47.35% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -41.84% | -86.64% | -175.79% | -168.69% | -101.23% |
| Normalized Basic EPS | -36.83% | -78.57% | -166.98% | -184.99% | -101.18% |
| EPS Diluted | -41.84% | -86.64% | -175.79% | -168.69% | -101.23% |
| Normalized Diluted EPS | -36.83% | -78.57% | -166.98% | -184.99% | -101.18% |
| Average Basic Shares Outstanding | 91.30% | 18.10% | 1.19% | 6.62% | 0.99% |
| Average Diluted Shares Outstanding | 91.30% | 18.10% | 1.19% | 6.62% | 0.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |